BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer

Patients with high-risk, nonmuscle-invasive bladder cancer (NMIBC) frequently relapse after standard intravesical bacillus Calmette-Guérin (BCG) therapy and may have a dismal outcome. The mechanisms of resistance to such immunotherapy remain poorly understood. Here, using cancer cell lines, freshly...

Descripción completa

Detalles Bibliográficos
Autores principales: Rouanne, Mathieu, Adam, Julien, Radulescu, Camélia, Letourneur, Diane, Bredel, Delphine, Mouraud, Séverine, Goubet, Anne-Gaëlle, Leduc, Marion, Chen, Noah, Tan, Tuan Zea, Signolle, Nicolas, Bigorgne, Amélie, Dussiot, Michael, Tselikas, Lambros, Susini, Sandrine, Danlos, François-Xavier, Schneider, Anna K., Chabanon, Roman, Vacher, Sophie, Bièche, Ivan, Lebret, Thierry, Allory, Yves, Soria, Jean-Charles, Arpaia, Nicholas, Kroemer, Guido, Kepp, Oliver, Thiery, Jean Paul, Zitvogel, Laurence, Marabelle, Aurélien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197524/
https://www.ncbi.nlm.nih.gov/pubmed/35503263
http://dx.doi.org/10.1172/JCI145666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197524/
https://www.ncbi.nlm.nih.gov/pubmed/35503263
http://dx.doi.org/10.1172/JCI145666

Ejemplares similares